MegaMD KRX:133750KOSDAQ

메가엠디 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked1since Sep 11

In Q3 2026, MegaMD reported revenue of ₩8.7bn, down 6.2% year on year, and operating profit of ₩1.0bn. MegaMD (메가엠디) appeared in 0 Korean news articles and 1 DART filing over the past seven days.

MegaMD today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates MegaMD stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

MegaMD quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩8.7bn-6.2%₩1.0bn
margin 12.0%
₩1.4bn
Q2 2026––₩995m₩1.6bn
Q1 2026₩7.8bn-7.1%₩150m
margin 1.9%
₩1.9bn
Q4 2025 derived₩7.1bn+0.2%−₩570m
margin −8.0%
−₩609m
Q3 2025₩9.3bn-6.2%₩1.7bn
margin 17.9%
₩2.2bn
Q2 2025₩9.8bn-9.0%₩1.2bn
margin 12.4%
₩1.4bn
Q1 2025₩8.4bn-3.8%−₩492m
margin −5.9%
−₩194m
Q4 2024 derived₩7.1bn+6.0%−₩978m
margin −13.7%
₩368m

MegaMD ranks #1109 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

MegaMD top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest MegaMD news Korean headlines